Case Report: Clinical and Serological Hallmarks of Cytokine Release Syndrome in a Canine B Cell Lymphoma Patient Treated With Autologous CAR-T Cells
BackgroundChimeric antigen receptor-T (CAR-T) cells have transformed the treatment of human B cell malignancies. With the advent of CAR-T therapy, specific and in some cases severe toxicities have been documented with cytokine release syndrome (CRS) being the most frequently reported. As dogs develo...
Main Authors: | Matthew J. Atherton, Antonia Rotolo, Kumudhini P. Haran, Nicola J. Mason |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Veterinary Science |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fvets.2022.824982/full |
Similar Items
-
Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma
by: M. Kazim Panjwani, et al.
Published: (2020-01-01) -
CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
by: Joseph W. Fischer, et al.
Published: (2021-06-01) -
EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study
by: Felix Korell, et al.
Published: (2022-04-01) -
Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells
by: Ke Zeng, et al.
Published: (2023-07-01) -
Case report: CAR-T cell therapy-induced cardiac tamponade
by: Sacha Sarfati, et al.
Published: (2023-03-01)